GNA Biosolutions wins AACC’s Disruptive Technology Award
On July 30, 2018, GNA Biosolutions was named the winner of the
American Association of Clinical Chemistry’s (AACC)
first-ever Disruptive Technology Award.
GNA presented data on the company’s proprietary
Pulse Controlled Amplification (PCA) technology during a
featured session at the 70th AACC Annual Scientific Meeting
& Clinical Lab Expo. The AACC Disruptive Technology Award
recognizes innovative testing solutions that improve
patient care through diagnostic performance or access
to high-quality testing.
Simplified molecular testing in minutes
GNA Biosolutions is a molecular technology company based in Martinsried, Germany. Our breakthrough technology, Pulse Controlled Amplification, transforms molecular testing by combining ultrafast nucleic acid amplification with intrinsic sample prep, to enable powerful solutions for the laboratory, on-site applications and the Point of Care.
Our vision is to bring the power of molecular testing, from sample to answer, to everyone, everywhere.